Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 25, 2020 - Issue 3
Submit an article Journal homepage
407
Views
10
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists

Raj A. Shaha Liver Institute Northwest, Seattle, WA, USAView further author information
,
Naim Alkhourib Texas Liver Institute, San Antonio, TX, USAView further author information
&
Kris V Kowdleya Liver Institute Northwest, Seattle, WA, USACorrespondence[email protected]
View further author information
Pages 251-260 | Received 30 May 2020, Accepted 14 Jul 2020, Published online: 12 Aug 2020

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jonathan Andrew Fallowfield, Maria Jimenez-Ramos & Andrew Robertson. (2021) Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opinion on Emerging Drugs 26:2, pages 149-163.
Read now

Articles from other publishers (9)

Wenxin Wang, Zhijun Cao, Zhongcheng Yang, Ya Chen, Huixin Yao, Danting Zhou, Peixin Ou, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Jiayi Xie, Ruojing Xiang, Yuanqian Yang, Yisi Chen, Yonghong Yang, Liyun Tan, Haolong Tang, Luyong Zhang & Zheng Li. (2023) Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists. European Journal of Medicinal Chemistry 258, pages 115614.
Crossref
Xiyue Shen, Kai Luo, Juntao Yuan, Junling Gao, Bingqing Cui, Zhuoran Yu & Zhongbing Lu. (2023) Hepatic DDAH1 mitigates hepatic steatosis and insulin resistance in obese mice: Involvement of reduced S100A11 expression. Acta Pharmaceutica Sinica B 13:8, pages 3352-3364.
Crossref
Na Zhang, Yuzhuo Wu, Wanchao Zhong, Guiyang Xia, Huan Xia, Lingyan Wang, Xiaohong Wei, Yi Li, Hongcai Shang, Hongwei He & Sheng Lin. (2022) Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy. Phytomedicine 102, pages 154148.
Crossref
Si-yu Tian, Shu-ming Chen, Cheng-xi Pan & Yong Li. (2022) FXR: structures, biology, and drug development for NASH and fibrosis diseases. Acta Pharmacologica Sinica 43:5, pages 1120-1132.
Crossref
Fen Wen, DeZhi Bian, XuDong Wu, RuoBing Liu, ChaoNan Wang & JianHe Gan. (2022) SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine‐ and choline‐deficient diet‐fed db/db mice . Chemical Biology & Drug Design 99:3, pages 504-511.
Crossref
Gary F Lewis & Robert A Hegele. (2022) Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. The Lancet Diabetes & Endocrinology 10:2, pages 142-148.
Crossref
Joseph Carpenter, Gang Wu, Ying Wang, Erica M. Cook, Tao Wang, Doree Sitkoff, Karen A. Rossi, Kathy Mosure, Xiaoliang Zhuo, Gary G. Cao, Milinda Ziegler, Anthony V. Azzara, Jack Krupinski, Matthew G. Soars, Bruce Alan Ellsworth & Dean A. Wacker. (2021) Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis. ACS Medicinal Chemistry Letters 12:9, pages 1413-1420.
Crossref
Michael Camilleri. (2021) New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders. Gastroenterology 161:3, pages 761-764.
Crossref
Katrin Panzitt, Peter Fickert & Martin Wagner. (2021) Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1867:2, pages 166017.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.